I agree with you tada that a smaller BP that Apabetalone doesn't disrupt should be interested in this. I opined some time back that it makes no sense for big BPs to not go after this if it actually works as good as we are told. If they bought it, they would control the roll out of it so that they would have the least cannibalism on their existing products and benefit when they did roll it out. If they let is slip to another BP, that BP can cannibalize their product and capitalize on the APL benefits also. It only makes sense for a BP to want to control everything which causes me concern that they don't step up.